Shufro Rose & Co’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-88,800
| Closed | -$302K | – | 316 |
|
|
2018
Q3 | $302K | Sell |
88,800
-3,000
| -3% | -$10.8K | 0.03% | 228 |
|
|
2018
Q2 | $345K | Buy |
91,800
+19,000
| +26% | +$92.5K | 0.03% | 209 |
|
|
2018
Q1 | $298K | Buy |
72,800
+5,000
| +7% | +$23.3K | 0.03% | 227 |
|
|
2017
Q4 | $315K | Sell |
67,800
-2,600
| -4% | -$14.3K | 0.03% | 216 |
|
|
2017
Q3 | $500K | Hold |
70,400
| – | – | 0.05% | 162 |
|
|
2017
Q2 | $509K | Sell |
70,400
-2,800
| -4% | -$17.5K | 0.05% | 155 |
|
|
2017
Q1 | $451K | Buy |
73,200
+500
| +0.7% | +$2.74K | 0.05% | 163 |
|
|
2016
Q4 | $426K | Buy |
72,700
+500
| +0.7% | +$2.73K | 0.05% | 169 |
|
|
2016
Q3 | $383K | Sell |
72,200
-5,800
| -7% | -$31.3K | 0.04% | 179 |
|
|
2016
Q2 | $516K | Buy |
78,000
+22,900
| +42% | +$128K | 0.06% | 155 |
|
|
2016
Q1 | $257K | Sell |
55,100
-3,500
| -6% | -$14K | 0.03% | 220 |
|
|
2015
Q4 | $295K | Sell |
58,600
-2,800
| -5% | -$13.3K | 0.03% | 193 |
|
|
2015
Q3 | $216K | Buy |
61,400
+26,700
| +77% | +$179K | 0.03% | 219 |
|
|
2015
Q2 | $346K | Buy |
+34,700
| New | +$372K | 0.04% | 190 |
|
Shufro Rose & Co's KERX Position: Q4 2018 in Review
Shufro Rose & Co sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 88,800 shares — an estimated $302K sold.
Shufro Rose & Co first reported a position in KERX in Q2 2015 and held it in 14 quarters. The position peaked at $516K in Q2 2016. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Shufro Rose & Co reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Shufro Rose & Co sold 88,800 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $302K.
- Shufro Rose & Co first reported a position in Keryx Biopharmaceuticals Inc in Q2 2015 and held it in 14 quarters.
- Shufro Rose & Co's Keryx Biopharmaceuticals Inc position peaked at $516K in Q2 2016.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Shufro Rose & Co's 13F filing for Q4 2018, filed 1 Feb 2019.